BioCardia Drops 9.45% Awaiting CardiAMP-HF Results

Biocardia's stock price dropped 9.45% in pre-market trading on April 1, 2025, reflecting investor sentiment and market dynamics.

BioCardia, a leader in cellular therapeutics for cardiovascular diseases, recently clarified the timing of its CardiAMP-HF results call to 4:30pm EDT. This announcement is significant as it provides investors with a clear timeline for the release of crucial data that could impact the company's stock performance.

On March 31, 2025, BioCardia announced the two-year outcomes of its Phase 3 CardiAMP-HF study. The results showed that its autologous cell therapy significantly improved survival, reduced major adverse cardiac and cerebrovascular events, and enhanced quality of life in ischemic heart failure patients with reduced ejection fraction. The study, involving 115 patients across 18 centers in the U.S. and Canada, showed particularly strong results in patients with elevated NTproBNP biomarkers, indicating the therapy’s potential to address a significant unmet need in heart failure treatment and reduce healthcare costs.

BioCardia has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings. This strong buy rating reflects the market's confidence in the company's potential for growth and success.